Jennifer Friel Goldstein

Head of Startup Banking; Head of Business Development and Strategic Initiatives

2023

Have REJOINED SVB (yes, SVB!!!) to help our clients and stakeholders continue to experience the best of SVB. I'm here to help you navigate all things Life Science and Healthcare, as well as operate our Startup Banking Division for all of Tech and Life Sciences. In addition to running our Startup Banking team across the US, I'm delighted to be involved in managing our Global Gateway and National Small Business teams too. Excited for what comes next for SVB and our community!

Managing Partner, Life Sciences & Healthcare, SVB Capital

2020 - 2023

Have joined SVB’s venture capital arm, SVB Capital, as Managing Partner to lead the firm’s new Life Science & Healthcare investment team and help stand up a life sciences direct investment fund. Headquartered in Silicon Valley, SVB Capital is a multi-strategy investment platform targeting the Innovation Economy with approximately $7.3B of assets under management across venture capital fund of funds, tech and life sciences direct funds, and credit funds. Since 1999, we have been the premier investment partner to global investors for accessing the Innovation Economy.

Head of Investor Coverage and Business Development, Technology & Healthcare

2019 - 2020

Bringing together our Business Development, Venture Capital Relationship Management, and Corporate Relationship Management teams across all sectors to deliver even greater ecosystem impact. Amazingly strong teams working together to support our partners, clients, and stakeholders. We are here to help innovators and the partners they depend upon.

Managing Director, Life Sciences; Senior Market Manager, West Coast and Accelerator

2017 - 2019

Expanded role to include all Western Region Healthcare verticals and teams. Significant P&L and management responsibilities ($15B portfolio and over 1,500 clients). Work with an amazing team to provide financing solutions, advice, and strategic introductions to our clients and stakeholders across the Life Sciences ecosystem. Practice has grown at 20-25% CAGR over this time. Additional responsibilities include managing our Strategic Advisory practice (buy side M&A) and creating/managing our National Accelerator practice, covering all pre-Series A healthcare clients in the U.S. Established strategic partnerships with critical Accelerators in our network

Managing Director, Head of Northwest Healthcare and National Biotech and Diagnostics practice

2015 - 2016

Expanded role to include National Biotech and Diagnostics responsibilities and Northwest Regional coverage of our other Healthcare verticals (Medical Device and Digital Health). Expanded team and formally created and executed on our National Corporate Venture Capital strategy. Extensive P&L growth and increased management responsibilities.

Managing Director, Biotech and Diagnostics, Bay Area

2012 - 2014

Responsible for all Northwest Biotech and Diagnostics banking clients and prospecting activities. Managed a team covering all aspects of our banking platform. In first 12 months, grew portfolio profitability by over 60%.

Board Member

2020 - 2023

Director, Venture Capital

2009 - 2012

Primary investing role. Participated in financings and/or board work for Ablexis (observer), DVS Sciences (observer), Five Prime (observer), Merus, Aquinox, Mirna, Flexion, and Epic Sciences. Led fund-of-fund investment decisions. Independently managed Pfizer's overall private equity portfolio for reporting and consolidation ($250M portfolio).

Portfolio and Decision Analysis

2006 - 2008

Decision making advisor for pipeline (R&D), commercial launch, and business development tradeoffs. Worked on launch / switch strategy for one of Pfizer's largest franchises. Advised on several divestitures and two royalty transactions. Created blueprint for alternative financing constructs that led to close coordination with Venture group.

BioPharma International

2005 - 2005

Developed non-primary market launch roadmap for key products based on market potential and reference-pricing strategies. Included pricing and direct versus distributor strategy, country by country. Presented modeling tool to management team for on-going launch assessment.

Senior Associate

2001 - 2004

Strategy consulting work across industries, with a strong focus on Private Equity transactions. Early promotion to Senior Associate. Wrote two industry white papers for publication

Robotics Research and Development

2000 - 2000

Trans-Regulation Intern

1998 - 1998

Production & Manufacturing Intern

1997 - 1998

In December 2003 Cytometrics was acquired by a team with many years experience in microcirculation research with the aim of improved customer support and further development of Cytoscan® technology.

Molecular Biology Department Intern

1996 - 1997